Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aipaluolituoweilimu plus nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2500105872Phase 2Completed
- Sponsor
- Xijing Hospital
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in Cervical Cancer (CC), sponsored by Xijing Hospital. Primary endpoint: Pathological complete response (pCR) rate. Started Jul 2025; status: completed.
02
Drugs
apalutamide
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500105872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105872.